Redefining Lipid-Based Delivery Vehicles with Novel Targeting Approaches & Formulation Strategies to Empower Precise, Tissue-Specific Delivery Beyond the Liver
Achieving precise extrahepatic delivery remains one of the biggest challenges in the LNP field. However, with AbbVie’s acquisition of Capstan Therapeutics and BMS’s acquisition of Orbital Therapeutics, the industry’s confidence in targeted LNPs has never been higher!
Returning to Boston in June 2026, the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit is bringing together industry pioneers and leading delivery experts to showcase the latest advances in novel targeting ligands and innovative lipid-based technologies. Across 3 jam-packed days, attendees will gain in-depth technical insights into accelerating the delivery of mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, adipose tissues, muscle, and more.
With world-class speakers from the likes of AbbVie, AstraZeneca, Novartis, Mote Therapeutics, Strand Therapeutics, and more, this is your premium opportunity to stay at the cutting-edge of extrahepatic targeting as well as collectively overcome challenges in targeted LNP analytics, scalability, and immunogenicity. Join this expert-led forum dedicated solely to delivery outside the liver and accelerate cell-specific LNPs towards the clinic.
“Attending this meeting provides a valuable chance to address common challenges and overcome biological obstacles in tissue-specific delivery through collaboration. Together, we can drive the advancement of innovative drug delivery solutions, ultimately driving better results for patients.”
Neha Kapate, Senior Scientist, AbbVie
“This conference is an incredible opportunity to share ideas and learn about the latest advances in extrahepatic delivery, a key step in making LNP technology work beyond the liver. These innovations could change how we treat disease by enabling precise, in vivo cell reprogramming. I’m excited to meet others who are passionate about this work and explore partnerships that can turn these breakthroughs into real solutions for patients.”
Hongjing Xia, Principal Scientist, Novartis
“Targeted LNP is crucial to enable the next wave of genetic medicine. However, targeted LNP drug product formulation is a complex process and there remains many unknowns. This conference offers an ideal opportunity to meet most relevant leaders in the field and collectively discuss the existing bottlenecks to expedite targeted LNP based drug product development. Alongside, excitedly looking forward to presentation and discussion to learn the current progress on targeted LNP.”
Pintu Kanjilal, Scientist, LNP Discovery, Strand Therapeutics
Explore the Full Event Guide
- 23+ expert speakers from pioneering biotech and large pharma, including AbbVie, Strand Therapeutics, AstraZeneca, Mote Therapeutics, Corner Therapeutics, Novo Nordisk, Novartis, and more
- Gain in-depth technical insights into achieving precise and selective delivery to muscle, adipose tissue, immune cells, and other extrahepatic targets
- 6 interactive workshops, roundtables and panel discussions to solve challenges in targeted LNP analytics, scalability as well as compare innovative solutions in passive and active targeting
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs shaping extrahepatic targeting, from novel targeting strategies to innovative non-viral formulations. Gain exclusive insights from industry leaders during data-driven presentations, interactive roundtables, and expert panel discussions.
Partner With Us
Showcase your solutions alongside other leading solution providers to a community dedicated to cutting-edge delivery innovation. Position your brand at the heart of the biopharma deals and partnerships defining RNA, cell, and gene therapy pipelines.
Join Biopharma Experts
Connect with LNP innovators and engage in the hottest conversations propelling safe, selective and specific extrahepatic delivery. During the dedicated networking sessions, make critical connections, and build meaningful collaborations.